Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07451431

Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain

The goal of this clinical trial is to learn if drug Mirogabalin works to treat diabetic peripheral neuropathic pain in adults. It will also learn about the safety of the drug Mirogabalin. The main questions it aims to answer are:

Does drug mirogabalin reduce neuropathic pain intensity? Is the drug mirogabalin safe in patients with diabetes suffering from neuropathic pain? Does drug mirogabalin improve patients' quality of life (QoL) ( physical, mental, and social well-being)? Researchers will compare drug mirogabalin to drug pregabalin (a drug conventionally used to treat diabetic neuropathic pain) to see if drug mirogabalin works to treat, safe and improve quality of life (QoL) in diabetic neuropathic pain.

Participants will:

Take drug Mirogabalin or pregabalin every day for 8 weeks Visit the clinic at 1, 2, 4, 6, 8 weeks for checkups

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

About this study

Diabetic Peripheral Neuropathic Pain (DPNP) is pain arising from abnormalities of the somatosensory system due to diabetes. It commonly manifests as burning or shooting pain, allodynia, and hyperalgesia, which interfere with sleep, mood, and daily activities. Pathophysiology involves hyperglycemia-induced nerve injury, sodium channel dysregulation, and central sensitization, resulting in complex pain states often resistant to standard analgesics.

Current first-line therapies for DPNP include pregabalin, duloxetine, and gabapentin. However, fewer than 50% of patients achieve adequate pain relief, and adverse effects such as somnolence and dizziness contribute to high discontinuation rates. Second- and third-line treatments, including tramadol, tapentadol, topical capsaicin, or lidocaine infusion, provide limited relief and are associated with safety or tolerability concerns.

Mirogabalin, a selective α₂δ-1 ligand, offers a potential improvement in the management of DPNP by targeting pain pathways while reducing CNS adverse effects. Its high-affinity binding to the α₂δ-1 subunit of voltage-gated calcium channels prolongs analgesia, while reduced activity at the α₂δ-2 subunit mitigates somnolence and dizziness. Phase III studies in Asian populations indicate comparable pain reduction to pregabalin, with fewer CNS side effects.

This study aims to evaluate and compare the efficacy, safety, and patient-reported outcomes of mirogabalin and pregabalin in patients with DPNP. The trial will provide robust data on pain reduction, adverse events, quality of life, and treatment satisfaction to guide optimal therapeutic strategies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥40 years) with diabetic neuropathy (Toronto score ≥6).
  • Persistent pain (NPS) despite standard therapy.
  • Stable diabetes management (HbA1c ≤8.5%).

Exclusion criteria

  • History of drug allergy to gabapentinoids.
  • Concurrent use of opioids or other neuropathic pain medications.
  • Pregnancy or lactation.
  • Cancer pain
  • Entraptment Radioculopathy

Treatment and study plan

Mirogabalin

Drug

Mirogabalin in diabetic peripheral neuropathic pain

Pregabalin

Drug

Pregabalin in diabetic peripheral neuropathic pain

Primary outcomes

  1. Neuropathic Pain Scale (NPS) score

    Time frame: baseline, 4 weeks, and 8 weeks

    Change in neuropathic pain intensity measured using the Neuropathic Pain Scale (NPS). Scores range from 0 to 100, with higher scores indicating more severe pain.

Secondary outcomes

  1. frequency and severity of adverse events

    Time frame: Week 1, 2, 4, 6, and 8

    Safety and tolerability, assessed by the frequency and severity of adverse events documented systematically using CTCAE v5.0 criteria

  2. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score

    Time frame: Weeks 1, 2, 4, 6, and 8

    Change in neuropathic pain intensity measured using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). Scores range from 0 to 24, with higher scores indicating more severe neuropathic pain.

Study contacts

Contact information is provided by the study sponsor or research team.

Kazi Mahzabin Arin, MD

CONTACT

[email protected]

+8801754057689

Sponsors and collaborators

Lead sponsor

Bangladesh Medical University

Other

Registry information

Official study title

Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 5, 2026
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.